This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Levosulpiride is indicated to treat dyspepsia, symptoms of Meniere's syndrome, and second line in the treatment of drug-induced nausea and vomiting.
- Generic Name
- Levosulpiride
- DrugBank Accession Number
- DB16021
- Background
Not Available
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Levosulpiride (DB16021)
- Weight
- Average: 341.43
Monoisotopic: 341.140927407 - Chemical Formula
- C15H23N3O4S
- Synonyms
- Levosulpirida
- Levosulpiride
- Levosulpiridum
- S-(-)-Sulpiride
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Symptomatic treatment of Dizziness •••••••••••• •••••••• • •••••• •••••• Treatment of Dyspepsia •••••••••••• •••••••••••• •••••••• •• ••••• ••••••••• •••••••• • •••••• •••••• Symptomatic treatment of Nausea •••••••••••• •••••••• • •••••• •••••• Symptomatic treatment of Nausea and vomiting •••••••••••• •••• •••• •••••• •••••••••• ••••••• •••••••• • •••••• •••••• Symptomatic treatment of Tinnitus •••••••••••• •••••••• • •••••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of CNS depression can be increased when 1,2-Benzodiazepine is combined with Levosulpiride. Acetazolamide The risk or severity of CNS depression can be increased when Acetazolamide is combined with Levosulpiride. Acetophenazine The risk or severity of CNS depression can be increased when Acetophenazine is combined with Levosulpiride. Agomelatine The risk or severity of CNS depression can be increased when Agomelatine is combined with Levosulpiride. Alfentanil The risk or severity of CNS depression can be increased when Alfentanil is combined with Levosulpiride. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image DIMOFLAX® ENZIMATICO TABLETAS RECUBIERTAS Levosulpiride (25 mg) + Pancrelipase (150 mg) + Simethicone (80 mg) Tablet, delayed release Oral C.I. FARMACAPSULAS S.A.S. - PLANTA NO. 2 2016-12-07 Not applicable Colombia 
LEPRIT® ENZIMATICOGRAGEAS Levosulpiride (25 mg) + Pancrelipase (150 mg) + Simethicone (80 mg) Tablet, coated Oral MANUFACTURERA MUNDIAL FARMACEUTICA S.A. 2010-12-15 Not applicable Colombia
Categories
- ATC Codes
- N05AL07 — Levosulpiride
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- JTG7R315LK
- CAS number
- 23672-07-3
- InChI Key
- BGRJTUBHPOOWDU-NSHDSACASA-N
- InChI
- InChI=1S/C15H23N3O4S/c1-3-18-8-4-5-11(18)10-17-15(19)13-9-12(23(16,20)21)6-7-14(13)22-2/h6-7,9,11H,3-5,8,10H2,1-2H3,(H,17,19)(H2,16,20,21)/t11-/m0/s1
- IUPAC Name
- N-{[(2S)-1-ethylpyrrolidin-2-yl]methyl}-2-methoxy-5-sulfamoylbenzamide
- SMILES
- CCN1CCC[C@H]1CNC(=O)C1=CC(=CC=C1OC)S(N)(=O)=O
References
- General References
- AIFA Product Information: LEVOSULPIRIDE FERRER (levosulpiride) oral [Link]
- External Links
- ChemSpider
- 599749
- ChEBI
- 64119
- ChEMBL
- CHEMBL267044
- ZINC
- ZINC000000057008
- Wikipedia
- Levosulpiride
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Recruiting Treatment Diabetic Macular Edema (DME) / Diabetic Retinopathy (DR) 1 2, 3 Completed Treatment Agitation 1 1 Completed Basic Science Dyspepsia 1 Not Available Completed Treatment Dyspepsia / Helicobacter Pylori Infection 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution / drops Oral Tablet, delayed release Oral Solution Oral 2.50 g Tablet Oral 25.000 mg Solution Oral 2.5 g Solution Oral 25 mg Solution Oral 2500 mg Tablet Oral 25 mg Solution / drops Oral 25 MG/ML Tablet, coated Oral Tablet Oral 2500000 mg Tablet Oral 100 MG Tablet Oral 50 MG Injection, solution Parenteral 12.5 MG/ML Injection, solution Parenteral 25 MG/ML Injection, solution Intravenous; Parenteral 50 MG/2ML Injection, solution Parenteral 25 MG/2ML Injection, solution 25 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.537 mg/mL ALOGPS logP 1.2 ALOGPS logP 0.22 Chemaxon logS -2.8 ALOGPS pKa (Strongest Acidic) 10.24 Chemaxon pKa (Strongest Basic) 8.39 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 101.73 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 88.63 m3·mol-1 Chemaxon Polarizability 35.59 Å3 Chemaxon Number of Rings 2 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS splash10-0006-0109000000-a150c1f709f2e19f6fa0 Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS splash10-0006-0039000000-adfb9cadd09fdd7b1ae4 Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS splash10-0gxy-3639000000-c4c7ffb9d048b60092eb Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9243000000-a608feb07261558cdc11 Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS splash10-03ej-6961000000-a257fecdf851e34e633c Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS splash10-004i-9020000000-7c7820bb8e6d0ef44d86 Predicted 1H NMR Spectrum 1D NMR Not Applicable Predicted 13C NMR Spectrum 1D NMR Not Applicable - Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 189.1566692 predictedDarkChem Lite v0.1.0 [M-H]- 168.14336 predictedDeepCCS 1.0 (2019) [M+H]+ 188.7196692 predictedDarkChem Lite v0.1.0 [M+H]+ 170.50137 predictedDeepCCS 1.0 (2019) [M+Na]+ 188.8165692 predictedDarkChem Lite v0.1.0 [M+Na]+ 177.503 predictedDeepCCS 1.0 (2019)
Drug created at December 14, 2020 14:09 / Updated at May 05, 2021 20:32